Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy

Human Molecular Genetics

Volumn 20, Issue 13, 2011, Pages 2662-2672

  Homma, Sachiko ^a   Beermann, Mary Lou ^a   Miller, Jeffrey Boone ^a,b  

^a BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GLIAL FIBRILLARY ACIDIC PROTEIN; LAMININ ALPHA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; LIFESPAN; LOCOMOTION; MOUSE; MUSCULAR DYSTROPHY; NERVE FIBER; NEWBORN; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCHWANN CELL; SCIATIC NERVE; VENTRAL ROOT; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL DIFFERENTIATION; DOXYCYCLINE; EARLY GROWTH RESPONSE PROTEIN 2; GENE EXPRESSION REGULATION; HUMANS; LAMININ; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; OCTAMER TRANSCRIPTION FACTOR-6; PERIPHERAL NERVES; SCHWANN CELLS; SCIATIC NERVE; SPINAL NERVE ROOTS;

MAMMALIA; MUS;

EID: 79958730202     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr168     Document Type: Article

References (53)

1. Patton, B.L., Miner, J.H., Chiu, A.Y. and Sanes, J.R. (1997) Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J. Cell Biol., 139, 1507-1521.
2. Patton, B.L., Wang, B., Tarumi, Y.S., Seburn, K.L. and Burgess, R.W. (2008) A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination. J. Cell Sci., 121, 1593-1604.
3. Muntoni, F. and Voit, T. (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord., 14, 635-649.
4. Reed, U.C. (2009) Congenital muscular dystrophy. Part I: a review of phenotypical and diagnostic aspects. Arq. Neuropsiquiatr., 67, 144-168.
5. Collins, J. and Bönnemann, C.G. (2010) Congenital muscular dystrophies: toward molecular therapeutic interventions. Curr. Neurol. Neurosci. Rep., 10, 83-91.
6. Rocha, C.T. and Hoffman, E.P. (2010) Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. Curr. Neurol. Neurosci. Rep., 10, 267-276.
7. Shorer, Z., Philpot, J., Muntoni, F., Sewry, C. and Dubowitz, V. (1995) Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J. Child Neurol., 10, 472-475.
8. Nakagawa, M., Miyagoe-Suzuki, Y., Ikezoe, K., Miyata, Y., Nonaka, I., Harii, K. and Takeda, S. (2001) Schwann cell myelination occurred without basal lamina formation in laminin a2 chain-null mutant (dy3K/dy3K) mice. Glia, 35, 101-110.
9. Guo, L.T., Zhang, X.U., Kuang, W., Xu, H., Liu, L.A., Vilquin, J.T., Miyagoe-Suzuki, Y., Takeda, S., Ruegg, M.A., Wewer, U.M. and Engvall, E. (2003) Laminin α2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul. Disord., 13, 207-215.
10. Bray, G.M. and Aguayo, A.J. (1975) Quantitative ultrastructural studies of the axon Schwann cell abnormality in spinal nerve roots from dystrophic mice. J. Neuropathol. Exp. Neurol., 34, 517-530.
11. Stirling, C.A. (1975) Abnormalities in Schwann cell sheaths in spinal nerve roots of dystrophic mice. J. Anat., 119, 169-180.
12. Bray, G.M., Perkins, S., Peterson, A.C. and Aguayo, A.J. (1977) Schwann cell multiplication deficit in nerve roots of newborn dystrophic mice. A radioautographic and ultrastructural study. J. Neurol. Sci., 32, 203-212.
13. Jaros, E. and Bradley, W.G. (1978) Development of the amyelinated lesion in the ventral root of the dystrophic mouse. Ultrastructural, quantitative and autoradiographic study. J. Neurol. Sci., 36, 317-339.
14. Perkins, C.S., Bray, G.M. and Aguayo, A.J. (1980) Persistent multiplication of axon-associated cells in the spinal roots of dystrophic mice. Neuropathol. Appl. Neurobiol., 6, 83-91.
15. Jaros, E. and Jenkinson, M. (1983) Quantitative studies of the abnormal axon-Schwann cell relationship in the peripheral motor and sensory nerves of the dystrophic mouse. Brain Res., 258, 181-196.
16. Kuang, W., Xu, H., Vachon, P.H., Liu, L., Loechel, F., Wewer, U.M. and Engvall, E. (1998) Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J. Clin. Invest., 102, 844-852.
17. Girgenrath, M., Dominov, J.A., Kostek, C.A. and Miller, J.B. (2004) Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J. Clin. Invest., 114, 1635-1639.
18. Girgenrath, M., Beermann, M.L., Vishnudas, V.K., Homma, S. and Miller, J.B. (2009) Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol., 65, 47-56.
19. Miller, J.B. and Girgenrath, M. (2006) The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol. Med., 12, 279-286.
20. Dominov, J.A., Kravetz, A.J., Ardelt, M., Kostek, C.A., Beermann, M.L. and Miller, J.B. (2005) Muscle-specific BCL2 expression ameliorates muscle disease in laminin-alpha2-deficient, but not dystrophin-deficient, mice. Hum. Mol. Genet., 14, 1029-1040.
21. Vishnudas, V.K. and Miller, J.B. (2009) Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. Hum. Mol. Genet., 18, 4467-4477.
22. Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmüller, H., Engvall, E., Müller, U. and Ruegg, M.A. (2001) An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature, 413, 302-307.
23. Hui, K., Kucera, J. and Henderson, J.T. (2008) Differential sensitivity of skeletal and fusimotor neurons to Bcl-2-mediated apoptosis during neuromuscular development. Cell Death Diff., 15, 691-699.
24. Yang, D., Bierman, J., Tarumi, Y.S., Zhong, Y.P., Rangwala, R., Proctor, T.M., Miyagoe-Suzuki, Y., Takeda, S., Miner, J.H., Sherman, L.S., Gold, B.G. and Patton, B.L. (2005) Coordinate control of axon defasciculation and myelination by laminin-2 and -8. J. Cell Biol., 168, 655-666.
25. Jessen, K.R., Morgan, L., Stewart, H.J. and Mirsky, R. (1990) Three markers of adult non-myelin-forming Schwann cells, 217c(Ran-1), A5E3 and GFAP: development and regulation by neuron-Schwann cell interactions. Development, 109, 91-103.
26. Zorick, T.S., Syroid, D.E., Arroyo, E., Scherer, S.S. and Lemke, G. (1996) The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation. Mol. Cell. Neurosci., 8, 129-145.
27. Arroyo, E.J., Bermingham, J.R. Jr., Rosenfeld, M.G. and Scherer, S.S. (1998) Promyelinating Schwann cells express Tst-1/SCIP/Oct-6. J. Neurosci., 18, 7891-7902.
28. Svaren, J. and Meijer, D. (2008) The molecular machinery of myelin gene transcription in Schwann cells. Glia, 56, 1541-1551.
29. Yu, W.M., Feltri, M.L., Wrabetz, L., Strickland, S. and Chen, Z.L. (2005) Schwann cell-specific ablation of laminin gamma1 causes apoptosis and prevents proliferation. J. Neurosci., 25, 4463-4472.
30. Chen, S., Rio, C., Ji, R.R., Dikkes, P., Coggeshall, R.E., Woolf, C.J. and Corfas, G. (2003) Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat. Neurosci., 6, 1186-1193.
31. Yu, W.M., Yu, H., Chen, Z.L. and Strickland, S. (2009) Disruption of laminin in the peripheral nervous system impedes nonmyelinating Schwann cell development and impairs nociceptive sensory function. Glia, 57, 850-859.
32. Yurchenco, P.D. and Patton, B.L. (2009) Developmental and pathogenic mechanisms of basement membrane assembly. Curr. Pharm. Des., 15, 1277-1294.
33. Chen, Z.L. and Strickland, S. (2003) Laminin gamma1 is critical for Schwann cell differentiation, axon myelination, and regeneration in the peripheral nerve. J. Cell Biol., 163, 889-899.
34. Okada, E., Mizuhira, V. and Nakamura, H. (1975) Abnormalities of the sciatic nerves of dystrophic mice, with reference to nerve counts and mean area of axons. Bull. Tokyo Med. Dent. Univ., 22, 25-43.
35. Relucio, J., Tzvetanova, I.D., Ao, W., Lindquist, S. and Colognato, H. (2009) Laminin alters fyn regulatory mechanisms and promotes oligodendrocyte development. J. Neurosci., 29, 11794-11806.
36. Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., Nabeshima, Y. and Takeda, S. (1997) Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett., 415, 33-39.
37. Davies, J.E., Wang, L., Garcia-Oroz, L., Cook, L.J., Vacher, C., O'Donovan, D.G. and Rubinsztein, D.C. (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med., 11, 672-677.
38. Alano, C.C., Kauppinen, T.M., Valls, A.V. and Swanson, R.A. (2006) Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl Acad. Sci. USA, 103, 9685-9690.
39. Sapadin, A.N. and Fleischmajer, R. (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol., 54, 258-265.
40. Yao, J.S., Shen, F., Young, W.L. and Yang, G.Y. (2007) Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem. Int., 50, 524-530.
41. Rodriguez-Granillo, G.A., Rodriguez-Granillo, A. and Milei, J. (2011) Effect of doxycycline on atherosclerosis: from bench to bedside. Recent Pat. Cardiovasc. Drug Discov., 6, 42-54.
42. Liu, H., Kim, Y., Chattopadhyay, S., Shubayev, I., Dolkas, J. and Shubayev, V.I. (2010) Matrix metalloproteinase inhibition enhances the rate of nerve regeneration in vivo by promoting dedifferentiation and mitosis of supporting Schwann cells. J. Neuropathol. Exp. Neurol., 69, 386-395.
43. Gawlik, K., Miyagoe-Suzuki, Y., Ekblom, P., Takeda, S. and Durbeej, M. (2004) Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. Hum. Mol. Genet., 13, 1775-1784.
44. Carmignac, V., Quéré, R. and Durbeej, M. (2011) Proteasome inhibition improves the muscle of laminin a2 chain-deficient mice. Hum. Mol. Genet., 20, 541-552.
45. Zdanowicz, M.M., Slonim, A.E., Bilaniuk, I., O'Connor, M.M., Moyse, J. and Teichberg, S. (1995) High protein diet has beneficial effects in murine muscular dystrophy. J. Nutr., 125, 1150-1158.
46. Connolly, A.M., Keeling, R.M., Streif, E.M., Pestronk, A. and Mehta, S. (2002) Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin alpha2-deficient mice. J. Neuroimmunol., 127, 80-87.
47. Lynch, G.S., Cuffe, S.A., Plant, D.R. and Gregorevic, P. (2001) IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul. Disord., 11, 260-268.
48. Hayes, A. and Williams, D.A. (1998) Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol. J. Neurol. Sci., 157, 122-128.
49. Meinen, S., Barzaghi, P., Lin, S., Lochmüller, H. and Ruegg, M.A. (2007) Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J. Cell Biol., 176, 979-993.
50. Gawlik, K.I. and Durbeej, M. (2010) Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan. Muscle Nerve, 42, 30-37.
51. Gawlik, K.I., Li, J.Y., Petersén, A. and Durbeej, M. (2006) Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy. Hum. Mol. Genet., 15, 2690-2700.
52. Gordon, P.H., Moore, D.H., Miller, R.G., Florence, J.M., Verheijde, J.L., Doorish, C., Hilton, J.F., Spitalny, G.M., MacArthur, R.B., Mitsumoto, H. et al., Western ALS Study Group. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 6, 1045-1053.
53. Minagar, A., Alexander, J.S., Schwendimann, R.N., Kelley, R.E., Gonzalez-Toledo, E., Jimenez, J.J., Mauro, L., Jy, W. and Smith, S.J. (2008) Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch. Neurol., 65, 199-204.